IDEAYA's Darovasertib Hits Primary Endpoint, NDA Filing Underway

What happened

IDEAYA announced that the Phase 2/3 OptimUM-02 registrational trial of darovasertib combination in uveal melanoma met its primary endpoint, a major milestone. Complete data will be presented at ASCO, and the company plans to initiate an RTOR submission in May, targeting NDA completion in H2 2026. The company reported $973M in cash as of March 31, 2026, with no change to cash runway guidance into 2030. While this is a clear positive catalyst, full efficacy and safety details remain undisclosed, and the stock already trades at a premium to cash. The binary risk has partially resolved, but investors should await ASCO data for a full assessment of the magnitude of benefit and competitive positioning.

Implication

If ASCO data confirm robust efficacy and tolerability, darovasertib could become a standard of care in uveal melanoma, supporting significant revenue potential. However, execution risk in regulatory filing, commercial launch, and pipeline diversification persist; long-term value hinges on maintaining momentum and expanding into additional indications.

Thesis delta

The prior cautious stance is now upgraded. The positive OptimUM-02 readout de-risks the lead asset and validates the platform, shifting the risk/reward toward more favorable. However, full data, regulatory progress, and execution on other pipeline assets remain critical to sustain upside. Stance moves from WAIT to POTENTIAL BUY, pending ASCO data.